SCHEMBL19069465

SCHEMBL19069465

Cc1noc(C)c1-c1ccc2[nH]c(=O)cc(-c3ccccc3)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 20/20 1.00
▸ CYP2C9 P11712 1/20 0.67
▸ BRD2 P25440 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19069445 0.90 BRD4 (1.00) BRD4CYP2C9BRD2
SCHEMBL16140983 0.82 BRD4 (0.73) BRD4CYP2C9
SCHEMBL16111487 0.82 BRD4 (1.00) BRD4CYP2C9
SCHEMBL16140991 0.80 BRD4 (1.00) BRD4CYP2C9
SCHEMBL17758369 0.80 BRD4 (0.68) BRD4CYP2C9
SCHEMBL17758368 0.80 BRD4 (0.68) BRD4CYP2C9
SCHEMBL16111268 0.76 BRD4 (1.00) BRD4CYP2C9BRD2
SCHEMBL16141005 0.75 BRD4 (1.00) BRD4CYP2C9BRD2
SCHEMBL17758375 0.75 BRD4 (1.00) BRD4CYP2C9
SCHEMBL16111861 0.75 BRD4 (1.00) BRD4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2020-07-21 — — US disclosed
US-20190345162-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2019-11-14 — — US disclosed
US-10266536-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2019-04-23 — — US disclosed
US-20180134715-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins CONVERGENE LLC 2018-05-17 — — US disclosed
US-9695179-B2 Methods and compositions for inhibition of bromodomain-containing proteins CONVERGENE LLC (US) 2017-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10717739-B2 Methods and compositions for inhibition of bromodomain-containing proteins BRPF3, BRD3, BRDT BRD4 4/4885CYP2C9 4826/4885BRD2 5/4885
US-20190345162-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins BRPF3, BRD3, BRDT BRD4 4/4885CYP2C9 4826/4885BRD2 5/4885
US-10266536-B2 Methods and compositions for inhibition of bromodomain-containing proteins BRPF3, BRD3, BRDT BRD4 4/4885CYP2C9 4826/4885BRD2 5/4885
US-20180134715-A1 Methods and Compositions for Inhibition of Bromodomain-Containing Proteins BRPF3, BRD3, BRDT BRD4 4/4885CYP2C9 4826/4885BRD2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback